Our laboratory has extensively studied tau oligomers in several neurodegenerative diseases including Alzheimer’s disease (AD) [11, 12], progressive supranuclear palsy (PSP) [26], traumatic brain injury (TBI) [27], and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) [28], as well as in synucleinopathies such as PD and DLB cases [29]. This evidence concerns the gene MAPT and neurodegenerative disease.